BIOCARDIA INC (BCDA)

Company Profile

BioCardia Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Sunnyvale, California and currently employs 16 full-time employees. BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.

Company Info

BIOCARDIA INC

320 Soquel Way

Sunnyvale CALIFORNIA 94070

P: 16502260123

CEO: Peter Altman

Employees: 18

Website: https://www.biocardia.com/